Hemostasis Products Market Report
Hemostasis Products Market size in 2020 is estimated to be $1.52 billion, growing at a CAGR of 4.6% during the forecast period 2021-2026. Hemostasis is the act of stopping blood flow from a damaged vessel or organ. Hemostasis products are the tools that help to control bleeding during surgery and also acts as Fresh Frozen Plasma. Hemostasis products help in fewer blood transfusions, decreased operating time, and reduced morbidity and mortality for patients. It contains Polysaccharides, Oxidized Regenerated Cellulose, which is a hemostatic agent used for hemostasis in surgery and eliminates the risk of viral transmission and increases patient safety. These products are very effective in cases of inhibited coagulation, independent of clotting ability. The increasing prevalence of chronic diseases such as cardiovascular diseases, cancer, Myocardial Infarction coupled with the rising incidence of trauma and accidents across the globe are the major factors driving the growth of the market. Moreover, growing technological advancement in hemostasis products coupled with rising usage of recombinant products further enhance the overall demand for the Hemostasis Products Market during the aforesaid period.
Hemostasis Products Market Report Coverage
The report: “Hemostasis Products Market – Forecast (2021-2026)”, by IndustryARC, covers an in-depth analysis of the following segments of the Hemostasis Products Market:
By Product Type: Topical Hemostasis Product, Infusible Hemostasis Product, Advanced Hemostasis Product
By Application: Trauma, Surgery, Hemophilia, Myocardial Infarction, Stroke, Thrombosis
By End User: Hospitals, Clinics, others
By Geography: North America (U.S, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Others), APAC (China, Japan India, SK, Aus and Others) South America (Brazil, Argentina and others), and RoW (Middle East and Africa)
In 2020, North America dominated the Hemostasis Products Market owing to the rising number of road accidents in the region.
Increasing development in healthcare infrastructure across the globe is driving the market growth of Hemostasis Products.
Detailed analysis of the Strength, Weakness, and opportunities of the prominent players operating in the market will be provided in the Hemostasis Products Market report.
The High cost of the products and some certain clinical limitation are challenging the growth of the market.
Hemostasis Products Market Segment Analysis - By Product Type
Based on the Technology, Hemostasis Products Market is segmented into Topical Hemostasis Product, Infusible Hemostasis Product, Advanced Hemostasis Product. The topical hemostasis product segment is estimated to dominate the market during the period 2021-2026. This is attributed to rising usage of topical hemostasis products during surgery, trauma to maintain hemostasis. Topical hemostasis products include polysaccharides, collagen, gelatin, and others. The advanced hemostasis products segment is forecast to be the fastest-growing segment and is projected to grow at a CAGR of 4.0% during the period 2021-2026. This is mainly owing due to the increased usage and product trust in surgical suites and it provides faster and more sustained hemostasis.
Hemostasis Products Market Segment Analysis - By Application
Based on the application, Hemostasis Products Market is segmented into Trauma, Surgery, Hemophilia, Myocardial Infarction, Stroke, and Thrombosis. In 2020, surgery is estimated to hold a major share in the market. This is mainly owing to the rising number of surgical procedures across the globe. Moreover, hemostasis products that contain thrombin which is safe and effective than alternative to gelatin sponges and oxidized cellulose in controlling bleeding during cardiac surgery are also contributing to the dominance of this segment. Also, trauma is projected to grow with a CAGR of 3.7% over the period 2021-2026. This is owing to the rising number of traumatic incidents including accidents.
Hemostasis Products Market Segment Analysis - By Geography
North America dominated the Hemostasis Products market share accounting for 40% of the market in 2020. This is mainly owing to the rising incidence of road accidents in countries such as the U.S. and Canada. According to, a report published by the U.S. Department of Transportation, National Highway Traffic Safety Administration, in 2018, there were 36,560 people killed in motor vehicle traffic crashes on U.S. roadways. However, the Europe region is projected to be the fastest-growing over the period 2021-2026. This is owing to rising expenditure on healthcare which leads to demand technologically advanced products owing to strong surgeries volume.
Hemostasis Products Market Drivers
Increasing Prevalence of Chronic Diseases
Increasing prevalence of chronic diseases such as cardiovascular diseases, cancer, Myocardial Infarction coupled is driving the growth of Hemostasis Products market. According to, National Centres for Disease Control and Prevention (CDC), chronic diseases such as cancer, diabetes, Myocardial Infarction are the leading cause of death in U.S. which accounts for nation’s $3.8 trillion in annual health care costs. Moreover, rising number of surgeries in outpatient settings owing rising geriatric population is also set to increase the market growth.
Rising Technological Advancement
Increase in research and development in products with a technologically advanced features is also driving the market. The advancement in R & D of the products reduces the risk of infection and transmission. For instance, TISSEEL the product offering by Baxter which is the most technologically advanced product contains fibrin sealant for surgical care. Also, the increasing adoption of recombinant products is also set to the growth of the Hemostasis Products Market.
Hemostasis Products Market Challenges
High capital expenditure required for these products owing to the usage of advanced technology for hemostat is challenging the market. Along with this the certain clinical limitation, which in some cases such as uncontrolled bleeding that leads to the limited adoption of these products are also further challenging the growth of the market.
Moreover, the outbreak of COVID-19 around the world has impacted all industries including the healthcare industry. Covid-19 affects the Hemostasis Products market including a drastic reduction in emergency surgical procedures and also overall admission to the Emergency department (ED). Also owing to the widespread of coronavirus, it affects non-essential medical procedures such as plastic surgery and others that are not linked to the treatment of COVID-19. These affect the Hemostasis Products market by the cancellation of scheduled surgery and shift of surgeons to the other area.
Hemostasis Products Market Industry Outlook
Product launches, Merger & Acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Hemostasis Products Market. Hemostasis Products top 10 companies are Baxter International, Inc., Medtronic, Johnson & Johnson, Pfizer, Inc., Cryolife, Inc., Stryker, Tricol Biomedical, Dexur, C. R. Bard, Inc., and Grifols, S.A.
In February 2020, Terumo launched AQUABRID, a new surgical sealant in the EMEA market. These product is optimized to stop bleeding during surgical procedure.
In June 2019, Baxter International, Inc. launched its new hemostasis product, Floseal Hemostatic Matrix. This product is approved by USFDA and helps to stop bleeding during the procedure.
Report Code: HCR 0517
Hemostasis And Tissue Sealing Agents Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2019 - 2024
Report Code: HCR 88102
1. Hemostasis Products Market Overview
1.1 Definitions and Scope
2. Hemostasis Products Market - Executive Summary
2.1 Market Size and Key Trends
2.2 Key trends by Product Type
2.3 Key trends by Application
2.4 Key trends by End-User
2.5 Key trends by Geography
3. Hemostasis Products Market Landscape
3.1 Market Share Analysis- Key Companies
3.2 Product Benchmarking- Key Companies
3.3 Financial Analysis - Key Companies
3.4 Patent Analysis
3.5 Pricing Analysis
4. Hemostasis Products Market - Startup companies Scenario Premium Premium
4.1 Key startup company Analysis by
4.1.3 Venture Capital and Funding Scenario
5. Hemostasis Products Market - Industry Market Entry Scenario Premium Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case Studies of successful ventures
6. Hemostasis Products Market Forces
6.1 Market Drivers
6.2 Market Constraints/Challenges
6.3 Porters Five Force Model
6.3.1 Bargaining Power of Suppliers
6.3.2 Bargaining Powers of Customers
6.3.3 Threat of New Entrants
6.3.4 Rivalry Among Existing Players
6.3.5 Threat of Substitutes
7. Hemostasis Products Market - Strategic Analysis
7.1 Value Chain Analysis
7.2 Opportunities Analysis
7.3 Market Life Cycle
8. Hemostasis Products Market – By Product Type (Market Size -$Million/$Billion)
8.1 Topical Hemostasis Product
8.2 Infusible Hemostasis Product
8.3 Advanced Hemostasis Product
9. Hemostasis Products Market – By Application (Market Size -$Million/$Billion)
9.4 Myocardial Infarction
10. Hemostasis Products Market- By End-user (Market Size -$Million/$Billion)
11. Hemostasis Products Market- By Geography (Market Size -$Million/$Billion)
11.1 North America
11.2.7 Rest of Europe
11.3.3 South Korea
11.4.5 Australia & New Zealand
11.4.6 Rest of Asia Pacific
11.4 South America
11.4.3 Rest of South America
11.5 Rest of the World
11.2.1 Middle East
12. Hemostasis Products Market – Entropy
13. Hemostasis Products Market - Industry / Segment Competition landscape Premium Premium
13.1 Market Share Analysis
13.1.1 Market Share by Country- Key companies
13.1.2 Market Share by Region- Key companies
13.1.3 Market Share at Global Level- Key companies
13.1.4 Best Practices for Companies
14. Hemostasis Products Market- Key Company List by Country Premium Premium
15. Hemostasis Products Market Company Analysis
15.1 Company Revenue, Products, M&A, Developments
15.2 Company 1
15.3 Company 2
15.4 Company 3
15.5 Company 4
15.6 Company 5
15.7 Company 6
15.8 Company 7
15.9 Company 8
15.10 Company 9
15.11 Company 10
"*Financials for private companies would be provided on a best efforts basis”.